Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | ADK | P55263 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12302023 | 1.00 | LMNA (0.75) | LMNAADKTDP1THRBSMN1; SMN2 | |
| SCHEMBL12302015 | 1.00 | LMNA (0.75) | LMNAADKTDP1THRBSMN1; SMN2 | |
| SCHEMBL12945763 | 1.00 | LMNA (0.75) | LMNAADKTDP1THRBSMN1; SMN2 | |
| SCHEMBL12029798 | 1.00 | LMNA (0.75) | LMNAADKTDP1THRBSMN1; SMN2 | |
| SCHEMBL13340646 | 1.00 | LMNA (0.75) | LMNAADKTDP1THRBSMN1; SMN2 | |
| SCHEMBL8196421 | 1.00 | LMNA (0.75) | LMNAADKTDP1THRBSMN1; SMN2 | |
| SCHEMBL285464 | 0.99 | LMNA (0.73) | LMNAADKTDP1THRBSMN1; SMN2 | |
| SCHEMBL8992747 | 0.99 | LMNA (0.73) | LMNAADKTDP1THRBSMN1; SMN2 | |
| SCHEMBL16508681 | 0.99 | LMNA (0.73) | LMNAADKTDP1THRBSMN1; SMN2 | |
| SCHEMBL16508671 | 0.99 | LMNA (0.73) | LMNAADKTDP1THRBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428213-A1 | STABILIZED CHLORITE SOLUTIONS IN COMBINATION WITH FLUOROPYRIMIDINES FOR USE IN CANCER TREATMENT | Nuvo Research AG (CH) | 2012-03-14 | — | — | EP | claimed |
| EP-2370414-A2 | PREPARATION OF CAPECITABINE | Dr. Reddy's Laboratories, Ltd. (IN) | 2011-10-05 | — | — | EP | claimed |
| US-20110224422-A1 | PREPARATION OF CAPECITABINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-09-15 | — | — | US | claimed |
| EP-2241556-A1 | METHOD FOR THE PREPARATION OF CAPECITABINE AND INTERMEDIATES USED IN SAID METHOD | Coll Farma S.L. (ES) | 2010-10-20 | — | — | EP | claimed |
| WO-2010065586-A2 | PREPARATION OF CAPECITABINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | WO | claimed |
| EP-0882734-B1 | 5'-Deoxy-cytidine derivatives | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | EP | claimed |
| EP-1060183-B1 | 5'-DEOXYCYTIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-04-23 | — | — | EP | claimed |
| US-6211166-B1 | COADMINISTERED WITH A 5-FLUOROURACIL DERIVATIVE; ANTICARCINOGENIC AGENTS | HOFFMAN-LA ROCHE INC. | 2001-04-03 | — | — | US | claimed |
| EP-0882734-A2 | 5'-Deoxy-cytidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-09 | — | — | EP | claimed |
| EP-0602454-B1 | N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines | HOFFMANN LA ROCHE (CH) | 1996-04-24 | — | — | EP | claimed |
| EP-0602454-A1 | N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines | F. HOFFMANN-LA ROCHE AG (CH) | 1994-06-22 | — | — | EP | claimed |
| CN-103601777-A | Preparation method of capecitabine | HARBIN PHARMACEUTICAL GROUP CO LTD GENERAL PHARMACEUTICAL FACTORY | 2014-02-26 | — | — | CN | disclosed |
| EP-2428213-A1 | STABILIZED CHLORITE SOLUTIONS IN COMBINATION WITH FLUOROPYRIMIDINES FOR USE IN CANCER TREATMENT | Nuvo Research AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-2370414-A2 | PREPARATION OF CAPECITABINE | Dr. Reddy's Laboratories, Ltd. (IN) | 2011-10-05 | — | — | EP | disclosed |
| US-20110224422-A1 | PREPARATION OF CAPECITABINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-09-15 | — | — | US | disclosed |
| EP-1060183-B1 | 5'-DEOXYCYTIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6211166-B1 | COADMINISTERED WITH A 5-FLUOROURACIL DERIVATIVE; ANTICARCINOGENIC AGENTS | HOFFMAN-LA ROCHE INC. | 2001-04-03 | — | — | US | disclosed |
| EP-0882734-A2 | 5'-Deoxy-cytidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-12-09 | — | — | EP | disclosed |
| EP-0602454-B1 | N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines | HOFFMANN LA ROCHE (CH) | 1996-04-24 | — | — | EP | disclosed |
| EP-0602454-A1 | N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines | F. HOFFMANN-LA ROCHE AG (CH) | 1994-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224422-A1 | PREPARATION OF CAPECITABINE | DPYD, TYMP, DCTD | LMNA 2368/4885ADK 1020/4885TDP1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.